The genetic architecture of the familial hyperlipidaemia syndromes: Rare mutations and common variants in multiple genes

Current Opinion in Lipidology

Volumn 25, Issue 4, 2014, Pages 274-281

  Talmud, Philippa J ^a   Futema, Marta ^a   Humphries, Steve E ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cascade testing; familial hypercholesterolaemia; gene score; polygenic

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR;

ALLELE; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; INHERITANCE; PRIORITY JOURNAL; REVIEW;

EID: 84904159029     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000090     Document Type: Review

References (35)

1. Schnabel RB, Baccarelli A, Lin H, et al. Next steps in cardiovascular disease genomic research-sequencing, epigenetics, and transcriptomics. Clin Chem 2012; 58:113-126.
2. Ford S Jr, Schubert WK, Glueck CJ, et al. Familial hyperchylomicronemia. Enzymatic and physiologic studies. Am J Med 1971; 50:536-541.
3. Auwerx JH, Babirak SP, Fujimoto WY, et al. Defective enzyme protein in lipoprotein lipase deficiency. Eur J Clin Invest 1989; 19:433-437.
4. Fojo SS, Brewer HB. Hypertriglyceridaemia due to genetic defects in lipoprotein lipase and apolipoprotein C-II. J Intern Med 1992; 231:669-677.
5. Johansen CT, Hegele RA. Genetic bases of hypertriglyceridemic phenotypes. Curr Opin Lipidol 2011; 22:247-253.
6. Seftel HC, Baker SG, Sandler MP, et al. A host of hypercholesterolaemic homozygotes in South Africa. Br Med J 1980; 281:633-636.
7. Benn M, Watts GF, Tybjaerg-Hansen A, et al. Familial hypercholesterolemia in the Danish general population: Prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97:3956-3964.
8. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490.
9. Usifo E, Leigh SE, Whittall RA, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: Update and pathological assessment. Ann Hum Genet 2012; 76:387-401.
10. Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: A mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990; 31:1337-1349.
11. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-156.
12. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292:1394-1398.
13. Goldstein JL, Hazzard WR, Schrott HG, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973; 52:1544-1568.
14. Nikkila EA, Aro A. Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet 1973; 1:954-959.
15. Brouwers MC, van Greevenbroek MM, Stehouwer CD, et al. The genetics of familial combined hyperlipidaemia. Nat Rev Endocrinol 2012; 8:352-362.
16. Mailly F, Palmen J, Talmud PJ, et al. Familial lipoprotein lipase (LPL) deficiency: A catalogue of LPL gene mutations identified in 20 patients from the UK, Sweden, and Italy. Hum Mutat 1997; 10:465-473.
17. Dorfmeister B, Zeng WW, Dichlberger A, et al. Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. Arterioscler Thromb Vasc Biol 2008; 28:1866-1871.
18. Surendran RP, Visser ME, Heemelaar S, et al. Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia. J Intern Med 2012; 272:185-196.
19. Futema M, Plagnol V, Whittall RA, et al. Use of targeted exome sequencing as a diagnostic tool for familial hypercholesterolaemia. J Med Genet 2012; 49:644-649.
20. Futema M, Whittall RA, Kiley A, et al. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic. Atherosclerosis 2013; 229:161-168.
21. Marques-Pinheiro A, Marduel M, Rabes JP, et al. A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1. Eur J Hum Genet 2010; 18:1236-1242.
22. Cenarro A, Garcia-Otin AL, Tejedor MT, et al. A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22. Clin Genet 2011; 79:475-481.
23. Wang X, Li X, Zhang YB, et al. Genome-wide linkage scan of a pedigree with familial hypercholesterolemia suggests susceptibility loci on chromosomes 3q25-26 and 21q22. PLoS ONE 2011; 6:e24838.
24. Thomas ER, Atanur SS, Norsworthy PJ, et al. Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia. Mol Genet Genomic Med 2013; 1:155-161.
25. MotazackerMM, Pirruccello J, Huijgen R, et al. Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia. Eur Heart J 2012; 33:1360-1366.
26. Vandrovcova J, Thomas ER, Atanur SS, et al. The use of next-generation sequencing in clinical diagnosis of familial hypercholesterolemia. Genet Med 2013; 15:948-957.
27. Benn M, Nordestgaard BG, Grande P, et al. PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol 2010; 55:2833-2842.
28. Stitziel NO, Fouchier SW, Sjouke B, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33:2909-2914.
29. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
30. Keating BJ, Tischfield S, Murray SS, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 2008; 3:e3583.
31. Shah S, Casas JP, Gaunt TR, et al. Influence of common genetic variation on blood lipid levels, cardiovascular risk and coronary events in two British prospective cohort studies. Eur Heart J 2013; 34:972-981.
32. Hegele RA, Ginsgerg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2013; S2213-8587:70191-70198.
33. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet 2013; 381:1293-1301.
34. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005; 180:155-160.
35. van de Woestijne AP, van der Graaf Y, de Bakker PI, et al. LDL-c linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease. Eur J Clin Invest 2013. [Epub ahead of print]